The relationship between laboratory-based outcome measures and mortality in end-stage renal disease: A systematic review

Hemodialysis International

Volumn 13, Issue 3, 2009, Pages 347-359

  Desai, Amar A ^c,d,e   Nissenson, Allen ^b   Chertow, Glenn M ^c,d   Farid, Mary ^c   Singh, Inder ^c   van Oijen, Martijn G H ^c,f   Esrailian, Eric ^b,c   Solomon, Matthew D ^b,c   Spiegel, Brennan M R ^a,b,c  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b STANFORD UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Biomarkers; Clinical performance measures; End stage renal disease (ESRD); Hemodialysis; Outcomes; Systematic review

Indexed keywords

ALBUMIN; BICARBONATE; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CALCIUM PHOSPHATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NATRIURETIC FACTOR; PARATHYROID HORMONE; PREALBUMIN; TROPONIN T; TUMOR NECROSIS FACTOR ALPHA; UREA;

ALBUMIN BLOOD LEVEL; ANEMIA; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIALYSIS; HEMATOCRIT; HUMAN; INFLAMMATION; KIDNEY FAILURE; LYMPHOCYTE COUNT; METABOLIC ACIDOSIS; MINERAL METABOLISM; MORTALITY; NUTRITIONAL STATUS; OUTCOME ASSESSMENT; REVIEW; SYSTEMATIC REVIEW;

HUMANS; KIDNEY FAILURE, CHRONIC; LABORATORY TECHNIQUES AND PROCEDURES; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 69249164165     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2009.00377.x     Document Type: Review

References (120)

1. NKF-K/DOQI. Clinical Practice Guidelines for Hemodialysis Adequacy. New York: National Kidney Foundation; 2001.
2. Goodkin DA. Does case mix explain the differences in dialysis mortality rates around the world? A report from the Dialysis Outcomes and Practice Patterns Study (DOPPS). iKidney-Nephrology Incite Issue 13, Spring 2005.
3. US Renal Data System. USRDS 2007 Annual Data Report. Bethesda, MD: National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2007.
4. Goodkin DA, Bragg-Gresham JL, Koenig KG, et al. Association of Comorbid Conditions and Mortality in Hemodialysis Patients in Europe, Japan, and the United States: The Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol. 2003; 14:3270-3277.
5. Lowrie EG, Lew NL. Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis. 1990; 15:458-482.
6. Locatelli F, Pisoni RL, Akizawa T, et al. Anemia management for hemodialysis patients: Kidney Disease Outcomes Quality Initiative (K/ DOQI) guidelines and Dialysis Outcomes and Practice Patterns Study (DOPPS) findings. Am J Kidney Dis. 2004; 44(Suppl 3):27-33.
7. Dialysis outcomes and practice patterns study-Overview. Available from: http://www.DOPPS.org (accessed date: December 2005).
8. Port FK, Pisoni RL, Bragg-Gresham JL, et al. DOPPS estimates of patient life years attributable to modifiable hemodialysis practice patterns in the United States. Blood Purif. 2004; 22:175-180.
9. Combe C, McCullough KP, Asano Y, Ginsberg N, Maroni BJ, Pifer TB. Kidney Disease Outcomes Quality Initiative (K/DOQI) and the Dialysis Outcomes and Practice Patterns Study (DOPPS): Nutrition guidelines, indicators, and practices. Am J Kidney Dis. 2004; 44(Suppl 3):39-46.
10. Saran R, Dykstra DM, Pisoni RL, et al. Timing of first cannulation and vascular access failure in haemodialysis: An analysis of practice patterns at dialysis facilities in the DOPPS. Nephrol Dial Transplant. 2004; 19:2334-2340.
11. Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2005; 67:1179-1187.
12. Pisoni RL, Bragg-Gresham JL, Young EW, et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004;44: 94-111.
13. Bommer J, Locatelli F, Satayathum S, et al. Association of predialysis serum bicarbonate levels with risk of mortality and hospitalization in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004; 44:661-671.
14. Himmelfarb J, Perreira BJ, Wesson DE, Smedberg PC, Henrich WL. Payment for quality in end stage renal disease. J Am Soc Nephrol. 2004; 15:3263-3269.
15. McClellan WM, Frankenfield DL, Frederick PR, Helgerson SD, Wish JB, Sugarman JR. Improving the care of ESRD patients: A success story. Health Care Financ Rev. 2003; 24:89-100.
16. Rocco MV, Frankenfield DL, Hopson SD, McClellan WM. Relationship between clinical performance measures and outcomes among patients receiving long-term hemodialysis. Ann Intern Med. 2006; 145:512-519.
17. McClellan WM, Flanders WD, Gutman RA. Variable mortality rates among dialysis treatment centers. Ann Intern Med. 1992; 117:332-336.
18. Centers for Medicare and Medicaid Services. 2002 Annual Report, End Stage Renal Disease Clinical performance Measures Project. Baltimore, MD: Department of Health and Human Services, Centers for Medicare and Medicaid Services, Center for Beneficiary Choices; 2002.
19. US Renal Data Systems. USRSD 2002 Annual Data Report: Atlas of End-Stage Renal Disease in the United Sates. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2002.
20. Lowrie EG, Teng M, Lacson E, Lew N, Lazarus M, Owen WF. Association between prevalent care process measures and facility specific mortality rates. Kidney Int. 2001; 60:1917-1929.
21. Lowrie EG, Lew NL. Commonly measured laboratory variables in hemodialysis patients: Relationships among them and to death risk. Semin Nephrol. 1992; 12:276-283.
22. Avram MM, Blaustein D, Fein PA, Goel N, Chattopadhyay J, Mittman N. Hemoglobin predicts long-term survival in dialysis patients: A 15-year single-center longitudinal study and a correlation trend between prealbumin and hemoglobin. Kidney Int. 2003:S6-S11.
23. Collins A, Ellefson J. Association between hematocrit level and mortality in hemodialysis patients. Case study of the anemic patient. Nephrol Nurs J. 2000; 27:233-236.
24. Collins AJ, Li S, St Peter W, et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol. 2001; 12:2465-2473.
25. Li S, Collins AJ. Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients. Kidney Int. 2004; 65:626-633.
26. Locatelli F, Pisoni RL, Combe C, et al. Anaemia in hemodialysis patients of five European countries: Association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2004; 19:121-132.
27. Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol. 1999; 10:610-619.
28. Ofsthun N, Labrecque J, Lacson E, Keen M, Lazarus JM. The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int. 2003; 63:1908-1914.
29. Pisoni RL, Bragg-Gresham JL, Young EW, et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004; 44:94-111.
30. Roberts TL, Foley RN, Weinhandl ED, Gilbertson DT, Collins AJ. Anaemia and mortality in haemodialysis patients: Interaction of propensity score for predicted anaemia and actual haemoglobin levels. Nephrol Dial Transplant. 2006; 21:1652-1662.
31. Robinson BM, Joffe MM, Berns JS, Pisoni RL, Port FK, Feldman HI. Anemia and mortality in hemodialysis patients: Accounting for morbidity and treatment variables updated over time. Kidney Int. 2005; 68:2323-2330.
32. Nakatani T, Naganuma T, Masuda C, et al. The prognostic role of atrial natriuretic peptides in hemodialysis patients. Blood Purif. 2003; 21:395-400.
33. Yoshihara F, Horio T, Nakamura S, et al. Adrenomedullin reflects cardiac dysfunction, excessive blood volume, and inflammation in hemodialysis patients. Kidney Int. 2005; 68:1355-1363.
34. Naganuma T, Sugimura K, Wada S, et al. The prognostic role of brain natriuretic peptides in hemodialysis patients. Am J Nephrol. 2002; 22:437-444.
35. Mallamaci F, Zoccali C, Tripepi G, et al. Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int. 2002; 61:609-614.
36. Burbea Z, Nakhoul F, Zoabi R, et al. Haptoglobin phenotype as a predictive factor of mortality in diabetic haemodialysis patients. Ann Clin Biochem. 2004; 41:469-473.
37. Kalantar-Zadeh K, Block G, Humphreys MH, McAllister CJ, Kopple JD. A low, rather than a high, total plasma homocysteine is an indicator of poor outcome in hemodialysis patients. J Am Soc Nephrol. 2004; 15:442-453.
38. Bayes B, Pastor MC, Bonal J, et al. Homocysteine, C-reactive protein, lipid peroxidation and mortality in haemodialysis patients. Nephrol Dial Transplant. 2003; 18:106-112.
39. Dierkes J, Domrose U, Westphal S, et al. Cardiac troponin T predicts mortality in patients with end-stage renal disease. Circulation. 2000; 102:1964-1969.
40. Ducloux D, Klein A, Kazory A, Devillard N, Chalopin JM. Impact of malnutrition-inflammation on the association between homocysteine and mortality. Kidney Int. 2006; 69:331-335.
41. Farkouh ME, Robbins MJ, Urooj Zafar M, et al. Association between troponin I levels and mortality in stable hemodialysis patients. Am J Med. 2003; 114:224-226.
42. Scott B, Deman A, Peeters P, et al. Cardiac troponin T and malondialdehyde modified plasma lipids in hemodialysis patients. Nephrol Dial Transplant. 2003; 18:737-742.
43. Iliou MC, Fumeron C, Benoit MO, et al. Prognostic value of cardiac markers in ESRD: Chronic Hemodialysis and New Cardiac Markers Evaluation (CHANCE) study. Am J Kidney Dis. 2003; 42:513-523.
44. Fernandez-Reyes MJ, Mon C, Heras M, et al. Predictive value of troponin T levels for ischemic heart disease and mortality in patients on hemodialysis. J Nephrol. 2004; 17:721-727.
45. Hocher B, Ziebig R, Altermann C, et al. Different impact of biomarkers as mortality predictors among diabetic and nondiabetic patients undergoing hemodialysis. J Am Soc Nephrol. 2003; 14:2329-2337.
46. Choy JB, Armstrong PW, Ulan RA, et al. Do cardiac troponins provide prognostic insight in hemodialysis patients? Can J Cardiol. 2003; 19:907-911.
47. Ooi DS, Veinot JP, Wells GA, House AA. Increased mortality in hemodialyzed patients with elevated serum troponin T: A one-year outcome study. Clin Biochem. 1999; 32:647-652.
48. Stolear JC, Georges B, Shita A, Verbeelen D. The predictive value of cardiac troponin T measurements in subjects on regular haemodialysis. Nephrol Dial Transplant. 1999; 14:1961-1967.
49. Ie EH, Klootwijk PJ, Weimar W, Zietse R. Significance of acute versus chronic troponin T elevation in dialysis patients. Nephron Clin Pract. 2004; 98:c87-c92.
50. Porter GA, Norton T, Bennett WB. Troponin T, a predictor of death in chronic haemodialysis patients. Eur Heart J. 1998; 19(Suppl N):N34-N37.
51. Wood GN, Keevil B, Gupta J, et al. Serum troponin T measurement in patients with chronic renal impairment predicts survival and vascular disease: A 2 year prospective study. Nephrol Dial Transplant. 2003; 18:1610-1615.
52. Mallamaci F, Zoccali C, Parlongo S, et al. Troponin is related to left ventricular mass and predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2002; 40:68-75.
53. Dierkes J, Domrose U, Westphal S, et al. Cardiac troponin T predicts mortality in patients with end-stage renal disease. Circulation. 2000; 102:1964-1969.
54. Conway B, McLaughlin M, Sharpe P, Harty J. Use of cardiac troponin T in diagnosis and prognosis of cardiac events in patients on chronic haemodialysis. Nephrol Dial Transplant. 2005; 20:2759-2764.
55. Hojs R, Ekart R, Hojs Fabjan T, Balon BP, Gorenjak M. Cardiac troponin T (cTnT) in hemodialysis patients with asymptomatic and symptomatic atherosclerosis. Arch Med Res. 2005; 36:367-371.
56. Iseki K, Yamazato M, Tozawa M, Takishita S. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int. 2002; 61:1887-1893.
57. Tschope W, Koch M, Thomas B, Ritz E. Serum lipids predict cardiac death in diabetic patients on maintenance hemodialysis. Results of a prospective study. The German Study Group Diabetes and Uremia. Nephron. 1993; 64:354-358.
58. Dwyer JT, Larive B, Leung J, et al. Are nutritional status indicators associated with mortality in the Hemodialysis (HEMO) Study? Kidney Int. 2005; 68:1766-1776.
59. Liu Y, Coresh J, Eustace JA, et al. Association between cholesterol level and mortality in dialysis patients: Role of inflammation and malnutrition. JAMA. 2004; 291:451-459.
60. Boger CA, Gotz A, Stubanus M, et al. C-reactive protein as predictor of death in end-stage diabetic nephropathy: Role of peripheral arterial disease. Kidney Int. 2005; 68:217-227.
61. Korevaar JC, van Manen JG, Dekker FW, de Waart DR, Boeschoten EW, Krediet RT. Effect of an increase in C-reactive protein level during a hemodialysis session on mortality. J Am Soc Nephrol. 2004; 15:2916-2922.
62. Nascimento MM, Pecoits-Filho R, Qureshi AR, et al. The prognostic impact of fluctuating levels of C-reactive protein in Brazilian haemodialysis patients: A prospective study. Nephrol Dial Transplant. 2004; 19:2803-2809.
63. Naganuma T, Sugimura K, Wada S, et al. The prognostic role of brain natriuretic peptides in hemodialysis patients. Am J Nephrol. 2002; 22:437-444.
64. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999; 55:648-658.
65. Tripepi G, Mallamaci F, Zoccali C. Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: Searching for the best risk marker by multivariate modeling. J Am Soc Nephrol. 2005; 16(Suppl 1):S83-S88.
66. Wanner C, Zimmermann J, Schwedler S, Metzger T. Inflammation and cardiovascular risk in dialysis patients. Kidney Int. 2002; 80(Suppl):99-102.
67. Schwedler SB, Metzger T, Schinzel R, Wanner C. Advanced glycation end products and mortality in hemodialysis patients. Kidney Int. 2002; 62:301-310.
68. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2000; 35:469-476.
69. Shinohara K, Shoji T, Emoto M, et al. Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol. 2002; 13:1894-1900.
70. Qureshi AR, Alvestrand A, Divino-Filho JC, et al. Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients. J Am Soc Nephrol. 2002; 13(Suppl 1):S28-S36.
71. Bologa RM, Levine DM, Parker TS, et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis. 1998; 32:107-114.
72. Kimmel PL, Phillips TM, Simmens SJ, et al. Immunologic function and survival in hemodialysis patients. Kidney Int. 1998; 54:236-244.
73. Rao M, Guo D, Perianayagam MC, et al. Plasma interleukin-6 predicts cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2005; 45:324-333.
74. Pecoits-Filho R, Barany P, Lindholm B, Heimburger O, Stenvinkel P. Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant. 2002; 17:1684-1688.
75. Futh R, Herder C, Forster S, et al. Evaluation of diagnostic relevance of mRNA levels in peripheral blood: Predictive value for mortality in hemodialysis patients. Cytokine. 2004; 27:166-172.
76. Spiegel DM, Raggi P, Smits G, Block GA. Factors associated with mortality in patients new to hemodialysis. Nephrol Dial Transplant. 2007; 22:3568-3572.
77. Okuno S, Ishimura E, Kitatani K, et al. Presence of abdominal aortic calcification is significantly associated with all-cause and cardiovascular mortality in maintenance hemodialysis patients. Am J Kidney Dis. 49:417-425.
78. Noordzij M, Korevaar JC, Boeschoten EW, Dekker FW, Bos WJ, Krediet RT. The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: Association with mortality in dialysis patients. Am J Kidney Dis. 2005; 46:925-932.
79. Marco MP, Craver L, Betriu A, Belart M, Fibla J, Fernandez E. Higher impact of mineral metabolism on cardiovascular mortality in a European hemodialysis population. Kidney Int. 2003; 85(Suppl):S111-S114.
80. Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: The USRDS waves 1, 3, and 4 study. J Am Soc Nephrol. 2005; 16:1788-1793.
81. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis. 1998; 31:607-617.
82. Morena M, Terrier N, Jaussent I, et al. Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J Am Soc Nephrol. 2006; 17:262-270.
83. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004; 15:2208-2218.
84. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001; 12:2131-2138.
85. Klassen PS, Lowrie EG, Reddan DN, et al. Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis. JAMA. 2002; 287:1548-1555.
86. Avram MM, Sreedhara R, Avram DK, Muchnick RA, Fein P. Enrollment parathyroid hormone level is a new marker of survival in hemodialysis and peritoneal dialysis therapy for uremia. Am J Kidney Dis. 1996; 28:924-930.
87. Guh JY, Chen HC, Chuang HY, Huang SC, Chien LC, Lai YH. Risk factors and risk for mortality of mild hypoparathyroidism in hemodialysis patients. Am J Kidney Dis. 2002; 39:1245-1254.
88. Kalantar-Zadeh K, Kilpatrick RD, Kuwae N, et al. Revisiting mortality predictability of serum albumin in the dialysis population: Time dependency, longitudinal changes and population-attributable fraction. Nephrol Dial Transplant. 2005; 20:1880-1888.
89. Sezer S, Ozdemir FN, Arat Z, Perim O, Turan M, Haberal M. The association of interdialytic weight gain with nutritional parameters and mortality risk in hemodialysis patients. Renal Failure. 2002; 24:37-48.
90. Goldwasser P, Michel MA, Collier J, et al. Prealbumin and lipoprotein(a) in hemodialysis: Relationships with patient and vascular access survival. Am J Kidney Dis. 1993; 22:215-225.
91. Ifudu O, Paul HR, Homel P, Friedman EA. Predictive value of functional status for mortality in patients on maintenance hemodialysis. Am J Nephrol. 1998; 18:109-116.
92. Comorbid conditions and correlations with mortality risk among 3,399 incident hemodialysis patients. Am J Kidney Dis. 1992; 20(Suppl 2):32-38.
93. Mesler DE, McCarthy EP, Byrne-Logan S, Ash AS, Moskowitz MA. Does the survival advantage of nonwhite dialysis patients persist after case mix adjustment? Am J Med. 1999; 106:300-306.
94. Maiorca R, Brunori G, Zubani R, et al. Predictive value of dialysis adequacy and nutritional indices for mortality and morbidity in CAPD and HD patients. A longitudinal study. Nephrol Dial Transplant. 1995; 10:2295-2305.
95. Owen WF Jr, Lew NL, Liu Y, Lowrie EG, Lazarus JM. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med. 1993; 329:1001-1006.
96. Collins AJ, Ma JZ, Umen A, Keshaviah P. Urea index and other predictors of hemodialysis patient survival. Am J Kidney Dis. 1994; 23:272-282.
97. Araujo IC, Kamimura MA, Draibe SA, et al. Nutritional parameters and mortality in incident hemodialysis patients. J Ren Nutr. 2006; 16:27-35.
98. Pifer TB, McCullough KP, Port FK, et al. Mortality risk in hemodialysis patients and changes in nutritional indicators: DOPPS. Kidney Int. 2002; 62:2238-2245.
99. Iseki K, Kawazoe N, Fukiyama K. Serum albumin is a strong predictor of death in chronic dialysis patients. Kidney Int. 1993; 44:115-119.
100. Chertow GM, Goldstein-Fuchs DJ, Lazarus JM, Kaysen GA. Prealbumin, mortality, and cause-specific hospitalization in hemodialysis patients. Kidney Int. 2005; 68:2794-2800.
101. Mittman N, Avram MM, Oo KK, Chattopadhyay J. Serum prealbumin predicts survival in hemodialysis and peritoneal dialysis: 10 years of prospective observation. Am J Kidney Dis. 2001; 38:1358-1364.
102. Sreedhara R, Avram MM, Blanco M, Batish R, Avram MM, Mittman N. Prealbumin is the best nutritional predictor of survival in hemodialysis and peritoneal dialysis. Am J Kidney Dis. 1996; 28:937-942.
103. Kuwae N, Kopple JD, Kalantar-Zadeh K. A low lymphocyte percentage is a predictor of mortality and hospitalization in hemodialysis patients. Clin Nephrol. 2005; 63:22-34.
104. Ates K, Ates A, Kutlay S, Nergizoglu G, Karatan O. Total lymphocyte count in peripheral blood of peritoneal dialysis patients: Relationship to clinical parameters and outcome. J Nephrol. 2004; 17:246-252.
105. Marshall MR, Byrne BG, Kerr PG, McDonald SP. Associations of hemodialysis dose and session length with mortality risk in Australian and New Zealand patients. Kidney Int. 2006; 69:1229-1236.
106. Hakim RM, Breyer J, Ismail N, Schulman G. Effects of dose of dialysis on morbidity and mortality. Am J Kidney Dis. 1994; 23:661-669.
107. Iseki K, Tozawa M, Takishita S. Determinants of prescribed dialysis dose and survival in a cohort of chronic hemodialysis patients. Clin Exp Nephrol. 2003; 7:231-237.
108. Salahudeen AK, Dykes P, May W. Risk factors for higher mortality at the highest levels of spKt/V in haemodialysis patients. Nephrol Dial Transplant. 2003; 18:1339-1344.
109. Salahudeen AK, Fleischmann EH, Bower JD. Impact of lower delivered Kt/V on the survival of overweight patients on hemodialysis. Kidney Int. 1999; 56:2254-2259.
110. Chertow GM, Owen WF, Lazarus JM, Lew NL, Lowrie EG. Exploring the reverse J-shaped curve between urea reduction ratio and mortality. Kidney Int. 1999; 56:1872-1878.
111. Held PJ, Port FK, Wolfe RA, et al. The dose of hemodialysis and patient mortality. Kidney Int. 1996; 50:550-556.
112. Himmelfarb J, Holbrook D, McMonagle E, Robinson R, Nye L, Spratt D. Kt/ V, nutritional parameters, serum cortisol, and insulin growth factor-1 levels and patient outcome in hemodialysis. Am J Kidney Dis. 1994; 24:473-479.
113. Charra B, Calemard E, Chazot C, et al. Dose of dialysis: What index? Blood Purif. 1992; 10:13-21.
114. Wolfe RA, Hulbert-Shearon TE, Ashby VB, Mahadevan S, Port FK. Improvements in dialysis patient mortality are associated with improvements in urea reduction ratio and hematocrit, 1999 to 2002. Am J Kidney Dis. 2005; 45:127-135.
115. Oksa H, Pasternack A, Pasanen M. Serum urea-creatinine ratio as a prognostic index in hemodialysis patients. Clin Nephrol. 1987; 27:125-130.
116. O'Connor AS, Leon JB, Sehgal AR. The relative predictive ability of four different measures of hemodialysis dose. Am J Kidney Dis. 2002; 40:1289-1294.
117. McClellan WM, Soucie JM, Flanders WD. Mortality in end-stage renal disease is associated with facility-to-facility differences in adequacy of hemodialysis. J Am Soc Nephrol. 1998; 9:1940-1947.
118. Kaysen GA, Schoenfeld PY. Albumin homeostasis in patients undergoing continuous ambulatory peritoneal dialysis. Kidney Int. 1984; 25:107-114.
119. Singh AK, Szczech L. CHOIR Investigators. et al. Correction of Anemia with epoetin alfa in chronic kidney disease. N Eng J Med. 2006; 355:2085-2098.
120. Fleming TR. Surrogate endpoints and FDA's accelerated approval process. Health Aff (Millwood). 2005; 24:67-78.